3.65
3.65 (0%)
As of Feb 05, 2025
Revance Therapeutics, Inc. [RVNC]
Source:
Company Overview
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings. Revance’s portfolio includes DAXXIFY for injection and the RHA Collection of dermal fillers in the U.S. Revance has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China.
| Country | United States |
| Headquarters | nashville, tennessee |
| Phone Number | (615) 724-7755 |
| Industry | manufacturing |
| CEO | Mark J. Foley |
| Website | www.revance.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $59.9 |
| Operating Profit | $-32.3 |
| Net Income | $-38.1 |
| Net Cash | $-80.1 |
Profit Ratios
| Gross Margin | $59.9 |
| Operating Margin | -53.9 |
| Profit as % of Revenues | -157.1% |
| Profit as % of Assets | -8.1% |
| Profit as % of Stockholder Equity | 23.4% |
Management Effectiveness
| Return on Equity | 23.4% |
| Return on Assets | -8.3% |
| Turnover Ratio | 12.7% |
| EBITA | $-31.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $461.6 |
| Total Liabilities | $624.6 |
| Operating Cash Flow | $-148.2 |
| Investing Cash Flow | $-15.3 |
| Financing Cash Flow | $83.3 |
